• Actuate Therapeutics received a U.S. patent notice of allowance covering oral elraglusib tablets, strengthening protection for its lead investigational cancer drug.
• A Phase 1/2 trial planned for the first quarter of 2027 will assess safety, tolerability and preliminary antitumor activity in advanced cancer.
• The daily tablet is designed to sustain drug exposure and GSK-3β inhibition, potentially enhancing antitumor immune responses.
• Preclinical and clinical exposure analyses identified plasma thresholds associated with clinical benefit, tumor growth inhibition and reduced tumor size.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Actuate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020800PRIMZONEFULLFEED9867772) on November 02, 2026, and is solely responsible for the information contained therein.